Krystal Biotech
KRYS
13 hedge funds and large institutions have $34M invested in Krystal Biotech in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, reducing their positions, and 5 closing their positions.
9% more capital invested
Capital invested by funds: $31.3M → $34M (+$2.72M)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.99% less ownership
Funds ownership: 32.6% → 31.6% (-0.99%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$743K |
| 2 |
AG
Artal Group
Luxembourg
|
+$501K |
| 3 |
Millennium Management
New York
|
+$253K |
| 4 |
Squarepoint
New York
|
+$108K |
| 5 |
TCP
Tourbillon Capital Partners
New York
|
+$23.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$534K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$137K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$26K |
| 4 |
FMA
FNY Managed Accounts
New York
|
-$23K |
| 5 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$5K |
KRYS Hedge Fund Activity: Q4 2017 in Review
13 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2017, worth a combined $34M — up 8.7% from $31.3M a quarter earlier.
Fund positioning in KRYS was balanced in Q4 2017: 5 funds opened new positions, 5 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $743K. The largest seller was Sabby Management, exiting entirely with an estimated $534K sold.
- 13 institutional investors held Krystal Biotech (KRYS) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $34M of Krystal Biotech stock for Q4 2017, up 8.7% quarter-over-quarter.
- 5 funds opened new Krystal Biotech positions in Q4 2017 and 5 closed out, a net change of 0 holders.
- The largest Krystal Biotech buyer in Q4 2017 was Vanguard Group, an estimated $743K added.
- The largest Krystal Biotech seller in Q4 2017 was Sabby Management, an estimated $534K sold.
Based on aggregated 13F filings for Q4 2017.